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We have used a bioinformatics approach for the identif ication and reconstruction
of metabolic pathways associated with amino acid metabolism in human mitochon-
dria. Human mitochondrial proteins determined by experimental and computa-
tional methods have been superposed on the reference pathways from the KEGG
database to identify mitochondrial pathways. Enzymes at the entry and exit points
for each reconstructed pathway were identif ied, and mitochondrial solute carrier
proteins were determined where applicable. Intermediate enzymes in the mito-
chondrial pathways were identif ied based on the annotations available from public
databases, evidence in current literature, or our MITOPRED program, which pre-
dicts the mitochondrial localization of proteins. Through integration of the data
derived from experimental, bibliographical, and computational sources, we recon-
structed the amino acid metabolic pathways in human mitochondria, which could
help better understand the mitochondrial metabolism and its role in human health.
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Introduction
Reconstruction of the metabolic maps of fully se-
quenced organisms is becoming a task of ma-
jor importance in order to help biologists iden-
tify and analyze the maps of newly sequenced or-
ganisms and newly found pathways (1 ). There
are several online databases that provide informa-
tion on metabolic content and pathway diagrams
for a majority of the fully sequenced microbes
and eukaryotic species. Databases such as EcoCyc
(http://ecocyc.org) describe the pathways of a sin-
gle organism (Escherichia coli), while others such as
KEGG (Kyoto Encyclopedia of Genes and Genomes;
http://www.genome.jp/kegg/) and MetaCyc (Ency-
clopedia of Metabolic pathways; http://metacyc.org)
provide pathway information on multiple organisms
including prokaryotic and eukaryotic species. How-
ever, none of these resources emphasize on the subcel-
lular localization of metabolic pathways, which is an
important part of pathway analysis given that many
biological pathways are distributed across more than
one subcellular location. Studies of this nature hold
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potential value to biomedical research areas such as
drug targeting, reconstruction of disease pathways,
understanding protein interaction networks, and an-
notation of new or alternative pathways.
A number of methods have been used for path-
way reconstruction by integrating a combination of
data determined by experimental and computational
means (2–4 ). Most of these methods have been de-
veloped to understand metabolic networks in prokary-
otic systems. However, reconstruction and functional
characterization of ATP production, heme synthesis,
and mixed phospholipid synthesis have been reported
in human mitochondria (5 ). Mitochondria are pri-
marily known as energy centers, while they also play
vital roles in the metabolism of many other biolog-
ical macromolecules including amino acids. Amino
acid metabolism has been well studied in the context
of cellular metabolism, but specific pathways eluci-
dating their subcellular localization to mitochondrial
organelles have not been reported before. Out of
20 amino acids, the metabolic pathways of 17 amino
acids utilize mitochondrial enzymes, and dysfunction
of these enzymes is the causative factor for over 40
known mitochondrial diseases or disorders in human
(partly in Table 1).
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Table 1 Diseases associated with the enzymes involved in the metabolism of amino acids
in human mitochondria
Pathway EC number Disease or disorder OMIM ID
Arginine degradation 2.1.1.2 Guanidinoacetate methyltransferase deficiency 601240
Arginine degradation 3.5.3.1 Argininemia 207800
Arginine metabolism 2.1.3.3 Ornithine transcarbamylase deficiency 311250
Arginine synthesis 2.6.1.13 Ornithinemia with gyrate atrophy of choroid and retina 258870
Asparatate/asparagine metabolism 6.4.1.1 Pyruvate carboxylase deficiency 266150
Glutamate metabolism 1.4.1.3 Hyperinsulinism-hyperammonemia syndrome (HHS) 606762
Glutamate/glutamine synthesis 1.5.1.12 Hyperprolinemia II 239510
Glutamine degradation 1.2.1.24 4-hydroxybutyricaciduria 271980
Glutamine degradation 2.6.1.19 GABA-transaminase deficiency 137150
Glutamine degradation 4.1.1.15 Pyridoxine-dependent infantile convulsions 266100
Glycine degradation 1.1.1.79 Hyperoxularia primary type II (HP 2) 260000
Glycine degradation 1.4.4.2 Nonketotic hyperglycinemia (NKH) 605899
Glycine degradation 2.1.2.10 NKH 605899
Isoleucine degradation 6.4.1.3 Beta-methylcrotonylglycinuria type II 210210
Leucine degradation 1.3.99.10 Isovalericacidemia 243500
Leucine degradation 2.8.3.5 Infantile ketoacidosis 245050
Lysine degradation 1.1.1.35 Hydroxyl-CoA dehydrogenase deficiency 300438
Lysine degradation 1.5.1.8 Hyperlysinemia 238700
Lysine degradation 2.3.1.61 Maple syrup urine disease type II 248610
Lysine degradation 2.3.1.9 Alpha-methylacetoaceticaciduria 203750
Lysine degradation 4.2.1.17 Trifunctional protein deficiency, type 2 607037
Lysine degradation 4.2.1.17 3-methylglutaconicaciduria 250950
Methionine degradation 1.2.4.4 Maple syrup urine disease 248600
Methionine degradation 5.4.99.2 Methylmalonicaciduria I (B12-unresponsive) 251000
Methionine degradation 6.4.1.3 Propionicacidemia 606054
Phenylalanine metabolism 1.14.16.1 Phenylketonuria 261600
Proline metabolism 1.5.1.12 Hyperprolinemia II 239510
Serine degradation 2.6.1.44 Oxalosis I (glycolicaciduria) 259900
& 2.6.1.51
Serine metabolism 2.1.2.10 NKH 605899
Serine metabolism 1.1.1.79 Hyperoxaluria primary type II 260000
Threonine degradation 1.4.3.4 Brunner syndrome 309850
Tyrosine metabolism 1.11.1.8 Defect in thyroid hormonogenesis II 274500
Valine degradation 1.1.1.31 3-hydroxyisobutyricaciduria 236795
Valine degradation 1.3.99.2 Short-chain acyl-CoA dehydrogenase deficiency 201470
Valine degradation 1.3.99.2 Medium-chain acyl-CoA dehydrogenase deficiency 201450
Valine degradation 5.4.99.2 Methylmalonicaciduria I (B12-unresponsive) 251000
Val/Leu/Ile degradation 1.2.1.3 Sjoegren-Larsson syndrome (SLS) 270200
Val, Leu, Ile degradation 1.2.4.4 Maple syrup urine disease 248600
The main goal of this study is to identify and an-
notate complete or partial segments of mitochondrial
pathways associated with amino acid metabolism in
human, and reconstruct these pathways by filling
in the gaps. We use a sequence-based homology
approach to identify mitochondrial pathways from
KEGG, search for literature-based annotations and
data from isozyme studies to systematically identify
the reactions, and also employ computational predic-
tion methods to identify proteins targeted to mito-
chondria. By effectively integrating all these data,
we have reconstructed a majority of the pathways as-
sociated with amino acid metabolism in human mito-
chondria.
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Results
Identification of amino acid pathways
associated with human mitochondria
A non-redundant set of human mitoproteome was
compiled from experimental, bibliographical, and
computational sources (see Materials and Methods).
KEGG database is the most comprehensive resource
on metabolic pathways, which builds maps based on
the Enzyme Classification (EC) numbers. In human,
KEGG mapping is available only for about 3,000 en-
zymes, since it fails to map the enzymes lacking EC
numbers. We have used a homology-based approach
to find the amino acid pathways associated with mi-
tochondria by searching the human mitoproteome set
against KEGG’s human proteome set.
Reconstruction of amino acid pathways
associated with human mitochondria
Plants and some bacteria are capable of synthesizing
all the 20 amino acids necessary for the formation
of proteins and other vital molecules; however, that
is not the case in mammals including human. Hu-
man can synthesize only 11 amino acids known as
“non-essential amino acids” while the other 9 (essen-
tial amino acids) need to be taken in the form of food.
Hence, essential amino acids have only catabolic path-
ways while the non-essential ones have both anabolic
and catabolic pathways. All the 20 amino acids ex-
cept histidine, alanine, and cysteine have metabolic
pathways associated with mitochondria. Neverthe-
less, these three amino acids are eventually converted
into pyruvate in cytosol, which enters into mitochon-
dria for consumption by the tricarboxylic acid (TCA)
cycle. Below, we provide the reconstructed metabolic
pathways and pathway maps for those amino acids as-
sociated with mitochondria. Note that some of them
are grouped together because they are connected in-
terdependently.
Lysine degradation
In human, lysine degradation is known to occur both
in mitochondria and cytosol, and here we describe
only the mitochondrial pathway (Figure 1). Lysine
is transported into mitochondria by ornithine carrier
that has two isoforms in human. Inside mitochondria,
lysine together with 2-ketoglutarate is first reduced
to saccharopine by lysine-ketoglutarate reductase (EC
1.5.1.8) and then to α-aminoadipate semialdehyde (α-
AAS) by saccharopine dehydrogenase (EC 1.5.1.9). In
human, there exists a bifunctional enzyme that can
catalyze both reactions. This protein is predicted as
mitochondrial by MITOPRED (100%) and its mouse
orthologue is also believed to be mitochondrial (6 ).
Fig. 1 Lysine–Tryptophan metabolism. 2-KG, 2-ketoglutarate; SP, saccharopine; α-ASS, α-aminoadipate semialde-
hyde; 2-α-AA, 2-α-aminoadipate; 2-OA, 2-oxoadipate; S-GDL, S-glutaryldihydrolipoamide; GCoA, glutaryl-CoA; CCoA,
crotonoyl-CoA; (S)-3-HBCoA, (S)-3-hydroxybutanoyl CoA; AACoA, acetoacetyl-CoA; ACoA, acetyl-CoA; TCA, tri-
carboxylic acid cycle; XAA, xanthurenic acid; 3-H,L-KYN, 3-hydroxy L-kynurenine; L-KYN, L-kynurenine.
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The next step is the conversion of α-AAS into 2-
α-aminoadipate (2-α-AA) by aminoadipate semialde-
hyde dehydrogenase (EC 1.2.1.31). The yeast ortho-
logue of this human protein (7 ) is predicted by MI-
TOPRED as mitochondrial (100%). The next enzyme
2-aminoadipate transaminase (EC 2.6.1.39) that cat-
alyzes the conversion of 2-α-AA into 2-oxoadipate (2-
OA) is localized in mitochondria. Eventually 2-OA
is converted into acetyl-CoA by a series of previously
well-known mitochondrial enzymes (8 ) as shown in
Figure 1.
Tryptophan degradation
Degradation of tryptophan takes place partly in
cytoplasm and partly in mitochondria. First,
tryptophan is catalyzed by two cytoplasmic en-
zymes (EC 1.13.11.11 and EC 3.5.1.9) to produce
L-kynurenine, which is further converted into 3-
hydroxy L-kynurenine by kynurenine monooxygenase
(EC 1.14.13.9), an outermembrane mitochondrial en-
zyme (8 ). Under normal conditions, 3-hydroxy L-
kynuranine is converted into 2-OA by a series of
cytoplasmic reactions, which is further transported
into mitochondria by oxodicarboxylate carrier in
a counter-exchange mechanism with 2-oxoglutarate.
Eventually 2-OA is converted into acetyl-CoA as
shown in the lysine degradation pathway (Figure 1).
Under infectious conditions, 3-hydroxy L-kynurenine
is converted into xanthurenic acid by kynurenine
aminotransferase-II (EC 2.6.1.7). The same enzyme
also catalyzes the conversion of L-kynurenine into
kynurenic acid in cytoplasm for which two known iso-
forms have been identified in human brain. One of
the isoforms is predicted as mitochondrial (99%) by
MITOPRED and its mouse orthologue has a mito-
chondrial isoform in brain tissue (9 ).
Phenylalanine degradation
Phenylalanine is utilized or degraded in mitochon-
dria by two different pathways. The first one is
the formation of phenylalanyl-tRNA by phenylalanyl-
tRNA synthetase (EC 6.1.1.20). In the second path-
way, it is converted into tyrosine by phenylalanine-
4-hydroxylase (PAH, EC 1.14.16.1) (10 ), which is
predicted by MITOPRED as mitochondrial (100%).
Gene mutation in PAH is associated with an autoso-
mal recessive disease known as phenylketonuria (Ta-
ble 1).
Tyrosine metabolism
Tyrosine is converted into tyrosyl-tRNA by a po-
tential mitochondrial isoform (as per the Swiss-Prot
database) of tyrosyl-tRNA synthetase (EC 6.1.1.1)
that is utilized in mitochondrial protein synthesis. In
another pathway (Figure 2), tyrosine is converted into
thyroxine in a series of reactions, all of which are
catalyzed by thyroid peroxidase (EC 1.11.1.8). The
mitochondrial localization of this protein is currently
unknown; however, thyroid peroxidase activity and
its intermediate products have been reported in hu-
man mitochondrial fractions (11 ). Moreover, there
are eight known isoforms to this enzyme, six of which
are predicted as mitochondrial by MITOPRED at var-
ious confidence levels ranging from 62% to 77%.
Fig. 2 Phenylalanine–Tyrosine metabolism. 3-I L-Tyrosine, 3-Ido L-Tyrosine; 3,5-DI L-Tyrosine, 3,5-Diido L-Tyrosine;
TI L-Tyronine, Triido L-Tyronine.
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Glycine metabolism
Glycine cleavage system (GCS) is a multienzyme com-
plex comprised of glycine decarboxylase (P-protein,
EC 1.4.4.2), aminomethyltransferase (T-protein, EC
2.1.2.10), lipoamide dehydrogenase (L-protein, EC
1.8.1.4), and a cosubstrate component H protein
(GCSH). This complex catalyzes oxidative cleavage
of glycine in a multistep reaction in almost all organ-
isms. GCS is loosely bound to the mitochondrial inner
membrane and the reaction is catalyzed in the mito-
chondrial matrix. Glycine degradation is catalyzed
by GCS in the presence of nicotinamide adenine din-
ucleotide (NAD) and tetrahydrofoliate (THF), re-
sulting in the production of CO2, ammonia, 5,10-
methylene THF, and NADH (reduced form of NAD)
as byproducts in multiple reactions (Figure 3). In an
alternative pathway, glycine degradation and synthe-
sis are reversibly catalyzed by serine hydroxymethyl-
transferase (EC 2.1.2.1), which is a pyridoxal phos-
phate dependent enzyme existing as both cytosolic
and mitochondrial isoforms.
Serine metabolism
There are three mitochondrial pathways involved in
the degradation or utilization of L-serine in mammals
(Figure 3), and considerable differences exist among
species in the relative contributions of these three
pathways. The first pathway operates inside the mi-
tochondrial matrix (8 ) in a three-step process. Ser-
ine is first converted into 3-hydroxypyruvate (3-HP)
by the mitochondrial alanine-glyoxylate transaminase
(AGT2, EC 2.6.1.44), followed by reduction of 3-HP
to glycerate by hydroxypyruvate dehydrogenease (EC
1.1.1.79). Dysfunction of the second enzyme leads
to hyperoxaluria type II disease in human (Table 1),
which has been identified as mitochondrial by MI-
TOPRED at 70% confidence. It was proposed that
the intermediates of this pathway are exchanged be-
tween mitochondria and cytoplasm since the previ-
ous and the next enzymes in the pathway are known
to be mitochondrial (12 ). Finally, glycerate is phos-
phorylated into 2-phosphoglycerate by mitochondrial
glycerate kinase (EC 2.7.1.31) before it is transported
Fig. 3 Serine–Glycine metabolism. 3-HP, 3-hydroxypyruvate; 2-PG, 2-phosphoglycerate; GCS, glycine cleavage system;
MTHF, methylene tetrahydrofoliate.
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into cytosol to take part in glycolysis. In human,
two putative isoforms, glycerate kinase 1 (GLYCK1)
and glycerate kinase 2 (GLYCK2), have been iden-
tified, but their subcellular locations remain un-
known. However, both proteins have been predicted
by MITOPRED as mitochondrial with 62% and 85%
confidence, respectively. In rat liver, this enzyme is
known to be localized in mitochondria and cytosol at
72% and 26% proportions, respectively (13 ).
In the second pathway, serine:pyruvate/alanine:
glyoxylate aminotransferase (SPT/AGT, EC 2.6.1.51)
converts serine into 3-HP that enters into glyoxylate
pathway under normal conditions. SPT/AGT exists
in the mitochondria of carnivores, the peroxisomes
of herbivores and human, and both the mitochon-
dria and peroxisomes of rodents. In human, it was
reported that AGT has lost its mitochondrial target-
ing signal by a point mutation in the initiation codon
and is localized to peroxisomes under normal condi-
tions (14 ). Nevertheless, it is mistargeted to mito-
chondrial matrix in patients with primary hyperox-
aluria type I (PH1), an inborn error of glyoxylate
metabolism characterized by increased excretion of
oxalate and glycolate (Table 1). The third pathway
in serine metabolism is the same as the alternative
metabolism of glycine synthesis and degradation.
Valine, leucine, and isoleucine degradation
Valine, leucine, and isoleucine are branched-chain
amino acids (BCAAs) and their degradation path-
ways are predominantly localized in mitochondria ex-
cept the first transamination step, which occurs in
cytoplasm (8 ). Cytoplasmic transamination steps
on BCCAs result in the production of correspond-
ing α-keto acids that are transported into mito-
chondria by mitochondrial carnitine shuttle mecha-
nism. Inside mitochondria, the first step is the ir-
reversible oxidative decarboxylation of α-keto acids
by a branched-chain α-keto acid dehydrogenase com-
plex (EC 1.2.4.4 and EC 2.3.1.–), yielding three
different CoA derivatives, that is, 3-methylbutanoyl-
CoA, isobutyryl-CoA, and 2-methylbutanoyl-CoA for
leucine, valine, and isoleucine keto acids. In the
case of leucine, 3-methylbutanoyl-CoA is converted
into 3-methylbut-2-enoyl-CoA by isovaleryl-CoA de-
hydrogenase (EC 1.3.99.10), while the acyl-CoAs of
valine and isoleucine are converted into methacrylyl-
CoA and trans-2-methylbut-2-enoyl-CoA respectively
by butyryl-CoA dehydrogenase (EC 1.3.99.2). An-
other mitochondrial enzyme, medium chain acyl-CoA
dehydrogenase (EC 1.3.99.3), also catalyzes the above
reactions for all the three acyl-CoAs, which is the
first reaction in the β-oxidation of mitochondrial fatty
acids. Enzymes involved in the rest of these pathways
resulting in the production of acetyl-CoA in leucine
and isoleucine degradation as well as succinyl-CoA in
valine degradation have been thoroughly illustrated
in the literature (8 ), and hence are not discussed here
in detail.
Threonine degradation
In mammals, there are two major L-threonine degra-
dation pathways. L-threonine is catabolized ei-
ther by L-serine/threonine dehydratase (SDH, EC
4.2.1.16) in cytoplasm or through the L-threonine 3-
dehydrogenase (TDH, EC 1.1.1.103) pathway in cyto-
plasm or mitochondria, independently. In the second
pathway, L-threonine is cleaved by TDH to produce 2-
amino-3-ketobutyrate, which is further converted into
glycine and acetyl-CoA by aminoacetone synthetase
(AAS, EC 2.3.1.29). However, in human, only AAS is
found to contain mitochondrial import sequence and
TDH turns out to be a pseudogene due to one or more
mutations that disrupt RNA splicing (15 ), indicat-
ing that this pathway is non-functional in human. In
an alternative pathway, 2-amino-3-ketobutyrate pro-
duced in cytoplasm is spontaneously decarboxylated
to aminoacetone (MetaCyc) and transported across
mitochondrial membranes, where it is converted into
2-oxopropanol by monoamine oxidase (EC 1.4.3.4),
an outer mitochondrial membrane enzyme (16 ). 2-
oxopropanol is further converted into pyruvate by
aldehyde dehydrogenase (EC 1.2.1.3) in mitochondria
and is consumed by the TCA cycle.
Methionine degradation
This pathway spans across cytoplasm and mitochon-
dria. In cytoplasm, methionine is activated in an
ATP-dependent reaction to form S-adenosyl methion-
ine (SAM), which is the major donor of methyl groups
in biosynthetic methylations. In a series of cytoplas-
mic reactions, SAM is converted into α-ketobutyrate,
which enters into mitochondria (MetaCyc). In mito-
chondria, α-ketobutyrate is converted into propionyl-
CoA by the mitochondrial α-ketobutyrate dehydro-
genase (EC 1.2.4.4) (17 ). Propionyl-CoA is con-
verted into D-methylmalonyl-CoA by propionyl-CoA
carboxylase (EC 6.4.1.3), then into L-methylmalonyl-
CoA by methylmalonyl-CoA racemase (EC 5.1.99.1),
and finally into succinyl-CoA by methylmalonyl-CoA
mutase (EC 5.4.99.2) that enters into the TCA cycle.
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Glutamate and glutamine metabolism
Glutamate/glutamine (Glu/Gln) metabolism is car-
ried out in different subcellular locations depend-
ing on the tissue type. In mitochondria, Glu/Gln
is synthesized in four different ways as described in
Figure 4: (1) Glutamate is formed by the reduc-
tive amination of α-ketoglutarate (from the TCA
cycle); (2) Glutamine and glutamate are intercon-
verted in an ATP-requiring reaction catalyzed by glu-
tamine synthetase (EC 6.3.1.2); (3) The previous re-
action with ammonia as a byproduct is also cat-
alyzed in a non-ATP requiring reaction by glutam-
inase (EC 3.5.1.2) in human brain, liver, and kid-
ney tissues; (4) The fourth precursor (an intermediate
from proline metabolism) for the synthesis of Glu/Gln
is 1-pyrroline-5-carboxylate (P5C), which is catalyzed
by 1-pyrroline-5-carboxylate dehydrogenase (P5CDh)
(EC 1.5.1.12) in mitochondrial matrix.
Degradation of Glu/Gln takes place via two
different pathways associated with mitochondria.
The first one is the conversion of glutamate into α-
ketoglutarate and ammonia by glutamate dehydroge-
nase (EC 1.4.1.3) that enters into the TCA cycle.
In the second pathway, glutamine is converted into
succinate in a three-step reaction, resulting in the
production of 4-aminobutanoate (GABA) and succi-
nate semialdehyde as intermediaries. This is a tissue-
specific pathway that occurs in liver, brain, and pan-
creatic islets (18 ). The enzymes involved in these
three successive reactions are glutamate decarboxy-
lase (GAD, EC 4.1.1.15), 4-aminobutyrate amino-
transferase (GABAT, EC 2.6.1.19), and succinate
semialdehyde dehydrogenase (SSADH, EC 1.2.1.24),
respectively. In human, GAD has two isoforms
(GAD65 and GAD67) encoded by individual genes,
and GAD67 is predicted as mitochondrial by MITO-
PRED (70%). In rat, GAD activity has been re-
ported in mitochondria (19 ). GABAT and SSADH
are known as mitochondrial enzymes.
Proline metabolism
Proline oxidase (EC 1.5.3.–) catalyzes the first step
in the degradation of proline and converts proline
into P5C in mitochondria, which is further degraded
into glutamate and explained in Glu/Gln metabolism
(Figure 4). P5CDh deficiency is associated with Type
Fig. 4 Glutamate–Glutamine–Arginine–Proline metabolism. Glu, glutamate; Gln, glutamine; GABA, gamma-
aminobutyric acid; SSA, succinate semialdehyde; α-KG, α-ketoglutarate; L-Gl-γ-P, L-glutamyl-γ-phosphate; L-Gl-
γ-SA, L-glutamyl-γ-semialdehyde; P5C, pyrroline-5-carboxylate; ORT, ornithine; Amm, ammonia; CP, carbomyl phos-
phate; CIT, citrulline; ArgS, argininosuccinate; Arg, arginine; NO, nitric oxide; GA, guanidinoacetate.
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II hyperprolinemia, an autosomal recessive disorder
characterized by accumulation of P5C and proline
(Table 1).
Arginine metabolism
Synthesis of arginine is carried out in cytoplasm.
However, the precursors required for this process orig-
inate in mitochondria by the degradation of three
other amino acids, that is, glutamine, glutamate,
and proline (Figure 4). Glutamate is converted
into L-glutamyl-γ-phosphate followed by L-glutamyl-
γ-semialdehyde by a bifunctional enzyme, P5C syn-
thetase (EC 1.2.1.41 and EC 2.7.2.11). A sponta-
neous non-enzymatic reaction converts L-glutamyl-γ-
semialdehyde into ∆-P5C, which is also produced by
proline oxidase in proline degradation. P5C is con-
verted into ornithine by ornithine aminotransferase
(EC 2.6.1.13). Ornithine together with carbomyl
phosphate (CP) produces citrulline, and CP is pro-
duced in mitochondria by the degradation of gluta-
mate in a two-step process. The first reaction is cat-
alyzed by glutamate dehydrogenase (EC 1.4.1.3) that
produces α-ketoglutarate and ammonia, then ammo-
nia is utilized to produce CP in the second reaction
catalyzed by carbamoyl phosphate synthase (CPS1,
EC 6.3.4.16). CP and ornithine react to produce
citrulline, which is catalyzed by ornithine carbomyl-
transferase (EC 2.1.3.3). Citrulline enters into cyto-
plasm, and the following two steps are carried out by
two cytosolic enzymes associated with the outer mi-
tochondrial membrane. Citrulline is converted into
argininosuccinate and then into arginine by the ac-
tion of arginosuccinate synthetase (EC 6.3.4.5) and
arginosuccinate lyase (EC 4.3.2.1) respectively in cy-
toplasm.
Arginine degradation is accomplished in mito-
chondria by three different pathways, resulting in the
production of three compounds, including ∆-P5C, ni-
tric oxide (NO), and creatine. In the first pathway,
arginine is converted into ornithine by the mitochon-
drial arginase II (EC 3.5.3.1) and then into P5C. The
second pathway leads to the production of NO, cat-
alyzed by NO synthase (EC 1.14.13.39). The third
pathway results in the formation of guanidinoacetate
and then creatine by the actions of glycine amidino-
transferase (EC 2.1.4.1) and guanidine acetate-N-
methyltransferase (EC 2.1.1.2), respectively.
Aspartate/aspargine metabolism
Aspartate synthesis in mitochondria is initiated by
the pyruvate carboxylase (EC 6.4.1.1) that converts
pyruvate into oxaloacetate. Oxaloacetate is then con-
verted into aspartate by aspartate aminotransferase
(EC 2.6.1.1) and then into aspargine by aspargine
synthase (EC 6.3.5.4). The first two enzymes are mi-
tochondrial while the last enzyme has two cytosolic
isoforms, indicating that the last reaction is carried
out in cytosol.
Discussion
In this study, we have presented complete or par-
tial pathways associated with the metabolism of 17
amino acids in human mitochondria (Figure 5). Path-
ways for six of these amino acids (leucine, isoleucine,
valine, methionine, aspartate, and aspargine) have
been well characterized in the literature and hence
were not thoroughly discussed in this paper. For
the remaining 11 amino acids, pathways were recon-
structed by filling in the gaps in the existing pathways
that are primarily based on KEGG’s human path-
ways. MITOPRED predictions have been used to ob-
tain subcellular localization information for the en-
zymes lacking such information. For most of the pre-
dictions, literature-based evidence from human pro-
teins has been provided (see Supporting Online Ma-
terial). If such information is not available, then ev-
idence from other mammalian species or eukaryotic
species is used. Since most of these metabolic path-
ways span across multiple subcellular locations, sev-
eral transport mechanisms exist to import or export
the metabolites involved in these pathways into or out
of mitochondria. The outer mitochondrial membrane
(OMM) is freely permeable to small molecules less
than 6,000 Da. In contrast, the inner mitochondrial
membrane (IMM) regulates the flux of a large variety
of solutes between cytosol and mitochondrial matrix
using about 20 known mitochondrial carrier systems
encoded by the SLC25 family of genes in human (20 ).
In this study, we have provided known mitochondrial
solute carriers involved in the transport of metabolites
in appropriate pathways.
Most of the amino acid metabolic pathways span
across cytoplasmic and mitochondrial locations. Nev-
ertheless, other subcellular locations such as peroxi-
somes are also often associated. In the case of me-
thionine, valine, leucine, isoleucine, threonine, tryp-
tophan, arginine, and aspargine, the metabolic path-
ways are executed partly in cytoplasm and partly in
mitochondria. On the other hand, for glutamate and
glutamic acid, the pathways are localized in a tissue-
specific manner as described before. In some cases,
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Fig. 5 Overview of the amino acid metabolic network in human mitochondria. Shaded areas represent the cyto-
plasmic segments of the pathways. 2-KG, 2-ketoglutarate; α-AAS, α-aminoadipate semialdehyde; 2-OA, 2-oxoadipate;
XAA, xanthurenic acid; 3-H,L-KYN, 3-hydroxy L-kynurenine; L-KYN, L-kynurenine; AACoA, acetoacetyl-CoA; ACoA,
acetyl-CoA; OA, oxaloacetate; 3-H-3-MGCoA, 3-hydroxy-3-methylglutaryl-CoA; 4-M-2-OP, 4-methyl-2-oxopentanoate;
SCoA, succinyl-CoA; α-KG, α-ketoglutarate; 3-M-2-OP, 3-methyl-2-oxopentanoate; 2-O-IP, 2-oxo-isopentanoate; MM,
methylmalonate; L-MMCoA, L-methylmalonyl-CoA; 2-OP, 2-oxopropanol; 2-A-3-KB, 2-amino-3-ketobutyrate; 5,10
MTHF, 5,10 methylene tetrahydrofliate; CP, carbomyl phosphate; CIT, citrulline; NO, nitric oxide; ORT, ornithine;
GA, guanidinoacetate; P5C, pyrroline-5-carboxylate; GABA, gamma-aminobutyric acid; SAM, S-adenosylmethionine.
parallel alternative pathways exist in multiple lo-
cations. In the case of glutamate metabolism,
the “transamination route” is in cytoplasm while
the “transdeamination route” takes place in mito-
chondria (8 ). The phosphorylated pathway of ser-
ine metabolism occurs in cytoplasm while the non-
phosphorylated pathway is found in mitochondria (8 ).
Glycine can be formed by two routes, both of which
involve serine. Glycine is formed from serine by serine
hydroxylmethyltransferase, which has both cytosolic
and mitochondrial isoforms, confirming that this re-
action occurs in both locations. The second route is
catalyzed by a mitochondrial enzyme, namely glycine
synthase (also known as the glycine cleavage system).
For a number of cases, location-specific isoforms exist
for catalyzing the same reaction in different subcellu-
lar locations.
It has been known that deficient or dysfunctional
mitochondrial proteins are causative factors for over
100 human diseases (http://www.neuro.wustl.edu/
neuromuscular/mitosyn.html), including Alzheimer’s
disease, Type II diabetes, Parkinson’s disease, can-
cer, apoptosis, and so on. We have identified all
the known human diseases associated with amino
acid metabolism in human mitochondria from the
OMIM database (Table 1). Experimental data on
the enzymes, substrates, products, and their carri-
ers have been collected and integrated from vari-
ous sources, including literature-based evidence and
database sources such as KEGG, ENZYME, and
Swiss-Prot. Studies of this nature pave the conceptual
basis for many experimental investigations to study
the system-wide implications of altering individual
components in metabolic pathways, which could help
better understand mitochondrial metabolism and its
role in human health.
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Materials and Methods
Collection of human mitochondrial pro-
tein sequences
Human mitochondrial protein sequences (nucleus-
encoded and targeted to mitochondria) were col-
lected from three different sources. The first set of
615 proteins was identified from the human heart
muscle by mass spectroscopy combined with rigor-
ous bioinformatics analysis (21 ). This set includes
a significant number of potentially new mitochon-
drial proteins, the biochemical functions of which are
yet to be determined. A second set (366 proteins)
was generated based on the annotations from pub-
lic data repositories (22 ). The third set of 810 pro-
teins was generated by a computational prediction
method, MITOPRED, which was developed by us
for the prediction of nucleus-encoded mitochondrial
proteins (23 ). MITOPRED predictions are based
on the differences in functional domains and amino
acid compositions between mitochondrial and non-
mitochondrial proteins. Redundant protein sequences
with 100% identity were removed and a final set of
1,439 human mitochondrial proteins (mitoproteome)
was used in this study. We used the KEGG database
(http://www.genome.ad.jp/kegg/) to get our refer-
ence set of metabolic pathways associated with amino
acid metabolism, and these pathways are merely used
as starting points.
Identification and reconstruction of
amino acid pathways in mitochondria
The mitoproteome dataset was compared against the
entire human proteome set in the KEGG database
and all matching sequences at 100% identity were se-
lected. Using this list, we have traced all the KEGG’s
pathways related to amino acid metabolism contain-
ing at least one mitochondrial protein sequence, and
finally identified 17 pathways. For each pathway, we
superposed the initial set of known mitochondrial en-
zymes on corresponding enzymes in the KEGG refer-
ence pathways to obtain a backbone map for recon-
struction. Using available literature, the start and
end points of each pathway invoked inside human mi-
tochondria were determined. Intermediate enzymes
that were not found in the backbone map were iden-
tified based on computational predictions from the
MITOPRED program, mostly validated by published
literature. Each predicted protein has been given a
prediction confidence value, which is the ratio of cal-
culated score to the total required score (for being
a mitochondrial sequence) and is expressed as a per-
centage. Isozyme data were also used to determine
mitochondrial associations in the case of ambiguous
annotations or proteins present in multiple pathways
belonging to different subcellular locations. Diseases
associated with the dysfunctions or deficiencies of mi-
tochondrial enzymes were identified from the OMIM
database (http://www.ncbi.nlm.nih.gov/omim).
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